Have you heard?
The Food and Drug Administration has approved Kymriah—a futuristic gene therapy meant to treat children and young adults with relapsed acute lymphoblastic leukemia by actually reprogramming an individual patient’s genes.
As eye-catching as that news, however, is the announcement that a single dose will cost $475,000. And that it comes with a money-back guarantee.
This article explains the cost and outlines concerns of patient advocacy group Patients for Affordable Drugs.